Search

Search Constraints

You searched for: Issue Volume 32(2022)Supplement 3

Search Results

81. 31/#204 Cost-effectiveness of hysterectomy at the time of risk-reducing bilateral salpingooophorectomy for patients with BRCA1 mutations. (4th December 2022)

87. 37/#877 Hormonal biomarkers remain prognostic relevant within the molecular classification in endometrial cancer. (4th December 2022)

89. 39/#452 Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the garnet study. (4th December 2022)